Rottweiler bites college student; street dog mauls pregnant woman

Bengaluru, Feb 13: UK's Chancellor of the Exchequer Sajid Javid quit the Boris Johnson government as part of a cabinet reshuffle unfolding on Thursday and has been replaced by Rishi Sunak, reports said.

Indian-descent Sunak, 39, who is married to Akshata, the daughter of Infosys co-founder N.R. Narayana Murthy, was Chief Secretary to the Treasury since July 2019.

An analyst with Goldman Sachs before joining politics in 2014, Sunak, whose grandparents were from Punjab and emigrated to the UK from east Africa, is MP from Richmond (Yorkshire). He was Parliamentary Under-Secretary of State for Local Government in the Theresa May government.

Pakistani-descent Javid, who became the first Asian to become a Cabinet Minister when he was made Secretary of State of culture, Media and Sports in the David Cameron government in 2014 after stints as Economic Secretary to the Treasury (2012-13) and Financial Secretary (2013-14), was earlier the Home Secretary in the the Theresa May government.

He had then cleared absconding businessman Vijay Mallya's extradition to India in February last year following the decision by the Westminister Magistrates Court in December 2018.

Javid, who ran for Conservative Party leadership after May quit but lost to Boris Johnson, was made Chancellor by the later. In the reshuffle on Thursday, he was offered to retain his post if he fired all his advisors but declined and quit, the BBC reported.

Mangaluru, Mar 16: As a precaution against the spread of Covid-19, the Karnataka State Road Transport Corporation (KSRTC) on Monday decided to cut down its premium, non-AC sleeper, Rajahamsa and express bus services from Mangaluru to Bengaluru and Kasaragod following poor patronage.

The cut down in services is as per the direction of KSRTC's Central office that wants bus services to be operated on priority.

KSRTC Mangaluru Divisional Controller S N Arun said that the corporation has decided to cut down 40 trips to Bengaluru. Concerning Kasaragod, it has reduced the number of trips from 40 to 35. "These include a reduction in services to Mysuru and Dharmasthala also," he added.

Bengaluru, Mar 27: Oncologist Dr. Vishal Rao, HCG Hospital Bengaluru on Friday said that human body cells release interferon chemical to kill viruses but it cannot be released by cells in the case of COVID-19 cases, leading to weak immune system. However, a therapy of specific concoction could be useful in treating COVID-19 patients.

"We got hold of some preprint suggesting that interferon is effective in COVID19," said Rao.

Speaking to news agency, he continued saying "When we withdraw blood for regular check-ups, we get buffy coat which can be used to take out cells and form interferon. These two chemicals and some other cytokines, in a specific concoction, could be potentially very useful in treating COVID-19 patients."

Rao said that they have built a concoction of cytokines which can be injected to reactivate immune system in COVID-19 patients.

"We are in a very initial stage and hope to be ready with its first set by this weekend. We have applied to the governement for an expedited review. We have also presented this before the state government" said Rao.

"We have a team of infection specialist, ICU team and other...all of us have worked together to build something that we believe. We want to serve the society at this hour of need," he added.

Dr Rao clarified that this is not a vaccine and this particular interferon therapy does not help to prevent the infection of COVID-19. However, this is focused and targeted towards COVID-19 positive patients or those who have just incubated the virus.

"We believe that in early stages as well as the patients who have just incubated, this particular therapy of interferon gama and other concoction of cytokines could be an effective method. In the late stages we are looking at specific dosage of the cells which are our own body cells which can actually be affective and could also be of use for the ventilator patients," he added.

Meanwhile, Dr Gururaj, Immunologist and Scientist told ANI that they are trying to cover two aspects, one is the early stage patients where they are trying to improve their immune systems.

"As Dr Vishal said, we are trying to see whether we can use the cytokines from our own immune cells which is a natural process but it is hampered in infected patients," said Dr Gururaj.

"In the last phase we are using cells which are used from the bone marrow of the patient or donors. We can use those cells to reduce the inflation and so called cytokines release syndrome which is basically the inflammatory response of the body," he added.